A study looking at a drug called E7449 in people with advanced solid tumours, or advanced B cell cancers
Cancer type:
Status:
Phase:
This study learnt more about a drug called E7449 for 
and cancers affecting cells called B cells. It was for people with cancer that had spread or came back after treatment.
E7449 is a type of that blocks a protein called PARP (a ). PARP repairs damage to in our cells. Blocking PARP may stop cancer cells being able to repair themselves.
The main aims of the study were to:
- find the best dose of E7449
- see how well this dose works in people with advanced cancer
The trial was open for people to join between 2012 and 2015. The team published the results in 2020.
Summary of results
This study found the best dose of E7449 to give.
Results
This was a study. 41 people with an advanced solid tumour took part. No one with a B cell cancer took part in the study.
E7449 is a tablet. It is taken once a day.
The first few people had a small dose of E7449. The next few had a higher dose and so on. The study team monitored people carefully to check for side effects. The best dose was the highest dose that did not cause too many side effects or too severe side effects. The team found that the best dose to give is 600mg.
The team looked at how well E7449 worked. They found that of the 41 people:
- the cancer had shrunk in 2 people
- the cancer stayed the same in 13 people
The team looked at tissue samples () taken when the people were diagnosed. They wanted to know if a substance () called 2X-121 DPR could show whether E7449 might work for people and how well it might work. They found that in 13 people 2X-121 DPR did predict how well E7449 worked.
Side effects
The most common side effects of E7449 were:
- tiredness (fatigue)
- red colouring of the urine
- feeling or being sick
- diarrhoea or constipation
- skin reactions such as a rash, colour changes, itching and dry skin
- loss of appetite
- depression
- increased sensitivity to light
- swelling around the eyes
Conclusion
The team concluded that:
- 600mg of E7449 is the best dose to give in future trials
- E7449 could help people with an advanced cancer
- the biomarker 2X-121 DPR can help to predict which people it might work best for
They said that further research should be done using E7449 and the biomarker 2x-121 DRP. They reported that there are 2 trials underway in Europe looking at this.
More detailed information
There is more information about this research in the reference below.
Please note, the information we link to here is not in plain English. It has been written for healthcare professionals and researchers.
R Plummer and others
British Journal of Cancer 2020. Volume 123, Issue 4, Pages 525 to 533.
Where this information comes from
We have based this summary on the information in the article above. This has been reviewed by independent specialists () and published in a medical journal. We have not analysed the data ourselves. As far as we are aware, the link we list above is active and the article is free and available to view.
Recruitment start:
Recruitment end:
How to join a clinical trial
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Chief Investigator
Professor Ruth Plummer
Supported by
Eisai
Experimental Cancer Medicine Centre (ECMC)
NIHR Clinical Research Network: Cancer
If you have questions about the trial please contact our cancer information nurses
Freephone 0808 800 4040
